How Whoop, Inc. Illegally Monetized Medical Misinformation

TLDR:

Whoop, Inc. sold high-priced “medical-grade” wearable devices and memberships while explicitly lacking the government authorization required to market such health tools.

The lying-ass company charged customers significant price premiums for a “Blood Pressure Insights” feature that the Food and Drug Administration (FDA) later labeled as unauthorized, misbranded, and potentially dangerous. While they promised clinical-level accuracy, the product remained legally unsalable and technically unverified, leaving thousands of health-conscious consumers with worthless hardware and unmonitored cardiovascular risks.

Continue reading to explore the specific ways this profit-first strategy bypassed safety regulations and exploited consumer trust.

The Medical-Grade Illusion: Profits Over Public Safety

Whoop, Inc. positioned its “Life” membership tier as a pinnacle of health technology, specifically marketing its “MG” device as a medical-grade heart and blood pressure screener.

This marketing strategy successfully convinced consumers to pay a $210 premium over the standard membership. The company promised daily systolic and diastolic blood pressure readings delivered directly to the wrist, an “unparalleled” insight previously reserved for clinical settings.

The reality behind this premium pricing involves a significant breach of consumer trust and federal safety standards. In July 2025, the FDA issued a formal warning that Whoop’s blood pressure feature had never been authorized for any use.

The government determined that Whoop was selling an unapproved medical device under the guise of a wellness tracker.

This corporate misconduct placed consumers at risk, as high blood pressure is a primary factor in heart attacks and strokes, and unverified readings can lead individuals to ignore life-threatening conditions.

A Timeline of Deception and Regulatory Conflict

The Neoliberal Incentive: Moving Fast and Breaking Laws

The corporate misconduct of Whoop, Inc. reflects a broader structural failure within neoliberal capitalism, where tech corporations treat regulatory compliance as a secondary concern to market capture.

By launching a medical feature without prior FDA approval, the company followed a well-worn path of “disruptive” growth that prioritizes immediate revenue over long-term safety. This strategy relies on the fact that regulatory agencies often react months after a product has already saturated the market and generated millions in subscription fees.

In this deregulated system, profit-maximization incentives encourage firms to operate in “legal gray zones.” Whoop marketed a feature intended to diagnose or treat disease (legal hallmarks of a medical device) while claiming it was merely for “wellness” to avoid the rigorous, expensive testing required for clinical tools. This evasion allowed the corpo to extract “rent” from consumers through high-cost annual subscriptions for technology that lacked the legal standing to be sold.

Exploiting Consumer Vulnerability for Shareholder Gain

The financial fallout of this misconduct falls entirely on the consumer.

Individuals purchased the Whoop “Life” tier specifically for the promised medical insights, making the blood pressure feature the primary driver of the sale. Because the product was misbranded and unauthorized at the time of purchase, it maintained zero legal value. Customers paid a “substantial price premium” for a product that could not lawfully fulfill its advertised purpose.

This extraction of wealth from the public is a hallmark of late-stage capitalism, where corporate “PR machines” use sophisticated branding to mask the absence of legitimate functionality. The company boasted of 99% accuracy in other metrics to build a “language of legitimacy,” which shielded the unverified nature of its most expensive feature.

While the company secured recurring revenue, the users were left with the risk of “erroneously low or high” readings that carry significant health consequences.

Systemic Failures and the Path Forward

This case illustrates that the current economic system frequently rewards corporations for treating safety regulations as optional hurdles. The ability of a firm to market “medical-grade” technology without government verification shows a breakdown in corporate accountability. True reform imo requires strengthening the ability of regulators to block the sale of unauthorized medical tech before it reaches the public, rather than reacting after the profit has already been harvested.